Sensorion Past Earnings Performance
Past criteria checks 0/6
Sensorion's earnings have been declining at an average annual rate of -18.8%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 23.6% per year.
Key information
-18.8%
Earnings growth rate
36.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 23.6% |
| Return on equity | -66.3% |
| Net Margin | -396.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sensorion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6 | -22 | 6 | 22 |
| 30 Sep 23 | 6 | -23 | 5 | 23 |
| 30 Jun 23 | 6 | -23 | 5 | 24 |
| 31 Mar 23 | 5 | -23 | 5 | 23 |
| 31 Dec 22 | 5 | -23 | 5 | 23 |
| 30 Sep 22 | 5 | -22 | 6 | 21 |
| 30 Jun 22 | 5 | -21 | 6 | 20 |
| 31 Mar 22 | 4 | -18 | 5 | 17 |
| 31 Dec 21 | 4 | -15 | 5 | 15 |
| 30 Sep 21 | 4 | -13 | 4 | 12 |
| 30 Jun 21 | 3 | -11 | 4 | 10 |
| 31 Mar 21 | 3 | -10 | 4 | 9 |
| 31 Dec 20 | 2 | -9 | 4 | 8 |
| 30 Sep 20 | 2 | -10 | 4 | 8 |
| 30 Jun 20 | 2 | -11 | 4 | 8 |
| 31 Mar 20 | 2 | -12 | 4 | 9 |
| 31 Dec 19 | 2 | -12 | 3 | 10 |
| 30 Sep 19 | 2 | -12 | 3 | 11 |
| 30 Jun 19 | 2 | -12 | 3 | 11 |
| 31 Mar 19 | 2 | -12 | 3 | 11 |
| 31 Dec 18 | 2 | -12 | 3 | 12 |
| 30 Sep 18 | 2 | -12 | 3 | 11 |
| 30 Jun 18 | 2 | -11 | 4 | 10 |
| 31 Mar 18 | 2 | -10 | 4 | 9 |
| 31 Dec 17 | 2 | -10 | 4 | 8 |
| 30 Sep 17 | 1 | -9 | 3 | 4 |
| 30 Jun 17 | 0 | -8 | 2 | 0 |
| 31 Mar 17 | 0 | -8 | 2 | 0 |
| 31 Dec 16 | 0 | -7 | 2 | 0 |
| 30 Sep 16 | 0 | -7 | 2 | 1 |
| 30 Jun 16 | 1 | -7 | 2 | 3 |
| 31 Mar 16 | 0 | -6 | 2 | 1 |
| 31 Dec 15 | 0 | -4 | 2 | 0 |
| 30 Sep 15 | 0 | -4 | 1 | 1 |
| 30 Jun 15 | 0 | -3 | 1 | 3 |
| 31 Mar 15 | 0 | -3 | 1 | 2 |
| 31 Dec 14 | 0 | -3 | 1 | 2 |
| 31 Dec 13 | 0 | -2 | 1 | 0 |
Quality Earnings: RFM is currently unprofitable.
Growing Profit Margin: RFM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RFM is unprofitable, and losses have increased over the past 5 years at a rate of 18.8% per year.
Accelerating Growth: Unable to compare RFM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RFM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: RFM has a negative Return on Equity (-66.31%), as it is currently unprofitable.